Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 182 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
CASE REPORT WITH REVIEW OF LITERATURE
Year : 2013  |  Volume : 17  |  Issue : 1  |  Page : 153-156

Adrenal incidentaloma and the Janus Kinase 2 V617F mutation: A case-based review of the literature


1 Division of Endocrinology, Adnan Menderes University Medical Faculty, Aydin, Turkey
2 Department of Internal Medicine, Adnan Menderes University Medical Faculty, Aydin, Turkey
3 Division of Hematology, Adnan Menderes University Medical Faculty, Aydin, Turkey
4 Department of General Surgery, Adnan Menderes University Medical Faculty, Aydin, Turkey
5 Department of Medical Biology and Genetics, Adnan Menderes University Medical Faculty, Aydin, Turkey

Correspondence Address:
Mustafa Unubol
Department of Internal Medicine, Adnan Menderes University Medical Faculty, Division of Endocrinology 09100, Aydin
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.107868

Rights and Permissions

Adrenal incidentaloma was detected in an 81-year-old male patient and a 37-year-old female patient who had been diagnosed with essential thrombocytosis. Each patient's Janus Kinase 2 (JAK2) V617F mutation was positive, and they were evaluated as having non-functional adrenal incidentaloma. The JAK2 activates the signal transducers and activators of transcription (STAT) proteins which then activate the phosphoinositol-3 kinases, Ras, mitogen-activated protein (MAP) kinases, and transcription. Constitutive activation causes cell proliferation and dysregulation of apoptosis. It is thought that STAT3 activation-mediated JAK family kinases have a central role in the solid tumor cell series. Permanent activation of STAT3 and STAT5 causes tumor cell proliferation, survival, metastasis, and an increase in tumor-mediated inflammation in solid and hematologic tumors. According to our literature screening, irregular JAK signaling, seen at the pathogenesis of many solid and hematologic tumors, has not been previously evaluated with regard to adrenal tumors. As a result, our cases are the first coexistence of JAK V617F mutation with adrenal incidentaloma in the literature. Because of this, we think that JAK2 mutation must be evaluated to clarify the etiology of adrenal incidentalomas.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1065    
    Printed28    
    Emailed0    
    PDF Downloaded237    
    Comments [Add]    

Recommend this journal